.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP05_Simeprevir.Simeprevir

Information

Simeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor that was used in combination with other antiviral agents for the treatment of chronic hepatitis C infection in adults. While it was approved by the FDA in 2013, its usage has largely been phased out in favor of newer direct-acting antivirals.

Pharmacokinetics

Pharmacokinetic parameters were reported in healthy adult volunteers after oral administration.

References

1. Valade, E, et al., & Ackaert, O (2018). Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. The AAPS journal 21(1) 1–None. DOI:10.1208/s12248-018-0272-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/30377854

2. Valade, E, et al., & Ackaert, O (2018). Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach. The AAPS journal 20(6) 111–None. DOI:10.1208/s12248-018-0271-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30350297

3. Snoeys, J, et al., & Ouwerkerk-Mahadevan, S (2017). Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clinical pharmacokinetics 56(7) 781–792. DOI:10.1007/s40262-016-0476-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27896690

Revisions

• 06/2025 initial generated model